| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Acronym | Name | Study Focus | Study Design | Clinical Variables | Participants with Phenotypes | Samples Sequenced | Additional Infomation | Consents | Accession | |||||||||||||||
2 | ACTIV4a | A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 (ACTIV4A) | COVID-19 | Interventional | N/A | 1,083 | N/A | General Research Use (GRU) | phs002694.v1.p1 | ||||||||||||||||
3 | ACTIV4b | COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 | COVID-19 | Interventional | N/A | 657 | N/A | General Research Use (GRU) | phs002710.v1.p1 | ||||||||||||||||
4 | AMISH | NHLBI TOPMed: Genetics of Cardiometabolic Health in the Amish | Cardiovascular Disease | Family/Twin/Trios | 76 | 1,069 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000956.v4.p1 | ||||||||||||||||
5 | AMISH | NHLBI TOPMed: Genetics of Cardiometabolic Health in the Amish | Cardiovascular Disease | Family/Twin/Trios | 76 | 1,123 | N/A | Health/Medical/Biomedical (IRB, MDS) (HMB-IRB-MDS) | phs000956.v4.p1 | ||||||||||||||||
6 | ARIC | NHLBI TOPMed - NHGRI CCDG: Atherosclerosis Risk in Communities (ARIC) | Cardiovascular Disease | Case-Control | 19 | 13,486 | 3,584 | Health/Medical/Biomedical (IRB) (HMB-IRB) | phs001211.v2.p2 | ||||||||||||||||
7 | ARIC | NHLBI TOPMed - NHGRI CCDG: Atherosclerosis Risk in Communities (ARIC) | Cardiovascular Disease | Case-Control | 19 | 60 | 1 | Disease-Specific (Cardiovascular Disease, IRB) (DS-CVD-IRB) | phs001211.v2.p2 | ||||||||||||||||
8 | BABYHUG | Hydroxyurea to Prevent Organ Damage in Children with Sickle Cell Anemia (BABY HUG) Phase III Clinical Trial and Follow-Up Observational Studies I and II | Sickle Cell Anemia | Clinical Trial | N/A | 219 | N/A | Cure SCi Metadata Catalog | General Research Use (GRU) | phs002415.v1.p1 | |||||||||||||||
9 | BAGS | NHLBI TOPMed: The Genetics and Epidemiology of Asthma in Barbados | Asthma | Family/Twin/Trios | 55 | 330 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs001143.v2.p1 | ||||||||||||||||
10 | BAGS | NHLBI TOPMed: The Genetics and Epidemiology of Asthma in Barbados | Asthma | Family/Twin/Trios | 55 | 1,527 | N/A | General Research Use (IRB) (GRU-IRB) | phs001143.v2.p1 | ||||||||||||||||
11 | C3PO | Clinical-trial of COVID-19 Convalescent Plasma in Outpatients | COVID-19 | Clinical Trial | 162 | 511 | N/A | General Research Use (GRU) | phs002752.v1.p1 | ||||||||||||||||
12 | CARDIA | Coronary Artery Risk Development in Young Adults (CARDIA) | Cardiovascular Disease | Prospective Longitudinal Cohort | 9,366 | 4 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000285.v3.p2 | ||||||||||||||||
13 | CARDIA | Coronary Artery Risk Development in Young Adults (CARDIA) | Cardiovascular Disease | Prospective Longitudinal Cohort | 9,366 | 3,111 | N/A | Health/Medical/Biomedical (IRB) (HMB-IRB) | phs000285.v3.p2 | ||||||||||||||||
14 | CARDIA | Coronary Artery Risk Development in Young Adults (CARDIA) | Cardiovascular Disease | Prospective Longitudinal Cohort | 9,366 | 511 | N/A | Health/Medical/Biomedical (IRB, NPU) (HMB-IRB-NPU) | phs000285.v3.p2 | ||||||||||||||||
15 | CATHGEN | CATHeterization GENetics (CATHGEN) | Coronary Disease | Cross-Sectional | 9 | 3,304 | N/A | Disease-Specific (Cardiovascular Disease, IRB) (DS-CVD-IRB) | phs000703.v1.p1 | ||||||||||||||||
16 | CCAF | The Cleveland Clinic Foundation's Lone Atrial Fibrillation GWAS Study | Atrial Fibrillation | Case Set | 15 | 543 | N/A | General Research Use (GRU) | phs000820.v1.p1 | ||||||||||||||||
17 | CCAF | NHLBI TOPMed: Cleveland Clinic Atrial Fibrillation (CCAF) Study | Atrial Fibrillation | Case Set | 39 | 2 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs001189.v3.p1 | ||||||||||||||||
18 | CCAF | NHLBI TOPMed: Cleveland Clinic Atrial Fibrillation (CCAF) Study | Atrial Fibrillation | Case Set | 39 | 363 | 315 | General Research Use (IRB) (GRU-IRB) | phs001189.v3.p1 | ||||||||||||||||
19 | CFS | NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe) | Sleep Apnea Syndromes | Prospective Longitudinal Cohort | 2,341 | 2,038 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000284.v2.p1 | ||||||||||||||||
20 | CFS | NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe) | Sleep Apnea Syndromes | Prospective Longitudinal Cohort | 2,341 | 1,473 | N/A | Disease-Specific (Heart, Lung, Blood, and Sleep Disorders, IRB, NPU) (DS-HLBS-IRB-NPU) | phs000284.v2.p1 | ||||||||||||||||
21 | CFS | NHLBI TOPMed: The Cleveland Family Study (CFS) | Sleep Apnea Syndromes | Prospective Longitudinal Cohort | 18 | 1,293 | 916 | Disease-Specific (Heart, Lung, Blood, and Sleep Disorders, IRB, NPU) (DS-HLBS-IRB-NPU) | phs000954.v3.p2 | ||||||||||||||||
22 | CHS | Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older | Cardiovascular Disease | Prospective Longitudinal Cohort | 14,719 | 3 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000287.v7.p1 | ||||||||||||||||
23 | CHS | Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older | Cardiovascular Disease | Prospective Longitudinal Cohort | 14,719 | 5,382 | N/A | Health/Medical/Biomedical (MDS) (HMB-MDS) | phs000287.v7.p1 | ||||||||||||||||
24 | CHS | Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older | Cardiovascular Disease | Prospective Longitudinal Cohort | 14,719 | 217 | N/A | Health/Medical/Biomedical (NPU, MDS) (HMB-NPU-MDS) | phs000287.v7.p1 | ||||||||||||||||
25 | CHS | Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older | Cardiovascular Disease | Prospective Longitudinal Cohort | 14,719 | 2 | N/A | Disease-Specific (Cardiovascular Disease, MDS) (DS-CVD-MDS) | phs000287.v7.p1 | ||||||||||||||||
26 | CHS | Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older | Cardiovascular Disease | Prospective Longitudinal Cohort | 14,719 | 8 | N/A | Disease-Specific (Cardiovascular Disease, NPU, MDS) (DS-CVD-NPU-MDS) | phs000287.v7.p1 | ||||||||||||||||
27 | CHS | NHLBI TOPMed: Cardiovascular Health Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 19 | 3,438 | 67 | Health/Medical/Biomedical (MDS) (HMB-MDS) | phs001368.v2.p2 | ||||||||||||||||
28 | CHS | NHLBI TOPMed: Cardiovascular Health Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 19 | 121 | 2 | Health/Medical/Biomedical (NPU, MDS) (HMB-NPU-MDS) | phs001368.v2.p2 | ||||||||||||||||
29 | CHS | NHLBI TOPMed: Cardiovascular Health Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 19 | 3 | N/A | Disease-Specific (Cardiovascular Disease, NPU, MDS) (DS-CVD-NPU-MDS) | phs001368.v2.p2 | ||||||||||||||||
30 | COPDGENE | Genetic Epidemiology of COPD (COPDGene) Funded by the National Heart, Lung, and Blood Institute | Pulmonary Disease, Chronic Obstructive | Case-Control | 343 | 12 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000179.v6.p2 | ||||||||||||||||
31 | COPDGENE | Genetic Epidemiology of COPD (COPDGene) Funded by the National Heart, Lung, and Blood Institute | Pulmonary Disease, Chronic Obstructive | Case-Control | 343 | 10,099 | N/A | Health/Medical/Biomedical (HMB) | phs000179.v6.p2 | ||||||||||||||||
32 | COPDGENE | Genetic Epidemiology of COPD (COPDGene) Funded by the National Heart, Lung, and Blood Institute | Pulmonary Disease, Chronic Obstructive | Case-Control | 343 | 272 | N/A | Disease-Specific (COPD and Smoking) (DS-CS) | phs000179.v6.p2 | ||||||||||||||||
33 | COPDGENE | NHLBI TOPMed: Genetic Epidemiology of COPD (COPDGene) in the TOPMed Program | Pulmonary Disease, Chronic Obstructive | Case-Control | 17 | 10,333 | 8,487 | Health/Medical/Biomedical (HMB) | phs000951.v4.p4 | ||||||||||||||||
34 | COPDGENE | NHLBI TOPMed: Genetic Epidemiology of COPD (COPDGene) in the TOPMed Program | Pulmonary Disease, Chronic Obstructive | Case-Control | 17 | 290 | 221 | Disease-Specific (COPD and Smoking, RD) (DS-CS-RD) | phs000951.v4.p4 | ||||||||||||||||
35 | CRA | NHLBI TOPMed: The Genetic Epidemiology of Asthma in Costa Rica | Asthma | Family/Twin/Trios | 40 | 311 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000988.v3.p1 | ||||||||||||||||
36 | CRA | NHLBI TOPMed: The Genetic Epidemiology of Asthma in Costa Rica | Asthma | Family/Twin/Trios | 40 | 3,478 | 1,040 | Disease-Specific (Asthma, IRB, MDS, RD) (DS-ASTHMA-IRB-MDS-RD) | phs000988.v3.p1 | ||||||||||||||||
37 | CSSCD | Cooperative Study of Sickle Cell Disease (CSSCD) | Sickle Cell Disease | Clinical Trial | N/A | 4,085 | N/A | Cure SCi Metadata Catalog | General Research Use (GRU) | phs002362.v1.p1 | |||||||||||||||
38 | DHS | NHLBI TOPMed: Diabetes Heart Study (DHS) African American Coronary Artery Calcification (AA CAC) | Cardiovascular Disease | Cross-Sectional | 56 | 576 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs001412.v1.p1 | ||||||||||||||||
39 | DHS | NHLBI TOPMed: Diabetes Heart Study (DHS) African American Coronary Artery Calcification (AA CAC) | Cardiovascular Disease | Cross-Sectional | 56 | 402 | 320 | Health/Medical/Biomedical (IRB, COL, NPU) (HMB-IRB-COL-NPU) | phs001412.v1.p1 | ||||||||||||||||
40 | DHS | NHLBI TOPMed: Diabetes Heart Study (DHS) African American Coronary Artery Calcification (AA CAC) | Cardiovascular Disease | Cross-Sectional | 56 | 3 | 2 | Disease-Specific (Diabetes and Heart Disease, IRB, COL, NPU) (DS-DHD-IRB-COL-NPU) | phs001412.v1.p1 | ||||||||||||||||
41 | ECLIPSE | Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) | Pulmonary Disease, Chronic Obstructive | Case-Control | 1,008 | 2,746 | N/A | Disease-Specific (Chronic Obstructive Pulmonary Disease, RD) (DS-COPD-RD) | phs001252.v1.p1 | ||||||||||||||||
42 | EOCOPD | NHLBI TOPMed: Boston Early-Onset COPD Study | Chronic Obstructive Pulmonary Disease | Family/Twin/Trios | 30 | 80 | 66 | Disease-Specific (COPD and Smoking, RD) (DS-CS-RD) | phs000946.v4.p1 | ||||||||||||||||
43 | FHS | Framingham Cohort | Cardiovascular Disease | Prospective Longitudinal Cohort | 62,944 | 3,117 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000007.v31.p12 | ||||||||||||||||
44 | FHS | Framingham Cohort | Cardiovascular Disease | Prospective Longitudinal Cohort | 62,944 | 13,070 | N/A | Health/Medical/Biomedical (IRB, MDS) (HMB-IRB-MDS) | phs000007.v31.p12 | ||||||||||||||||
45 | FHS | Framingham Cohort | Cardiovascular Disease | Prospective Longitudinal Cohort | 62,944 | 2,079 | N/A | Health/Medical/Biomedical (IRB, NPU, MDS) (HMB-IRB-NPU-MDS) | phs000007.v31.p12 | ||||||||||||||||
46 | FHS | NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 14 | 3,432 | 3,069 | Health/Medical/Biomedical (IRB, MDS) (HMB-IRB-MDS) | phs000974.v3.p2 | ||||||||||||||||
47 | FHS | NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 14 | 722 | 658 | Health/Medical/Biomedical (IRB, NPU, MDS) (HMB-IRB-NPU-MDS) | phs000974.v3.p2 | ||||||||||||||||
48 | GALAII | NHLBI TOPMed: Genes-environments and Admixture in Latino Asthmatics (GALA II) Study | Lung Diseases | Case Set | 15 | 4,941 | 912 | Disease-Specific (Lung Diseases, IRB, COL) (DS-LD-IRB-COL) | phs000920.v4.p2 | ||||||||||||||||
49 | GALAII | Genes-Environments and Admixture in Latino Asthmatics (GALA II) Study | Lung Diseases | Case-Control | 29 | 4 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs001180.v1.p1 | ||||||||||||||||
50 | GALAII | Genes-Environments and Admixture in Latino Asthmatics (GALA II) Study | Lung Diseases | Case-Control | 29 | 4,458 | N/A | Disease-Specific (Lung Disease, RD) (DS-LD-RD) | phs001180.v1.p1 | ||||||||||||||||
51 | GENESTAR | GeneSTAR (Genetic Study of Atherosclerosis Risk) NextGen Consortium: Functional Genomics of Platelet Aggregation Using iPS and Derived Megakaryocytes | Platelet Aggregation | Prospective Longitudinal Cohort | 131 | 164 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs001074.v1.p1 | ||||||||||||||||
52 | GENESTAR | GeneSTAR (Genetic Study of Atherosclerosis Risk) NextGen Consortium: Functional Genomics of Platelet Aggregation Using iPS and Derived Megakaryocytes | Platelet Aggregation | Prospective Longitudinal Cohort | 131 | 250 | N/A | Disease-Specific (Cardiovascular Disease, IRB, NPU, RD) (DS-CVD-IRB-NPU-RD) | phs001074.v1.p1 | ||||||||||||||||
53 | GENESTAR | NHLBI TOPMed: Genetic Study of Atherosclerosis Risk (GeneSTAR) | Platelet Aggregation | Prospective Longitudinal Cohort | 160 | 1,423 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs001218.v2.p1 | ||||||||||||||||
54 | GENESTAR | NHLBI TOPMed: Genetic Study of Atherosclerosis Risk (GeneSTAR) | Platelet Aggregation | Prospective Longitudinal Cohort | 160 | 1,787 | N/A | Disease-Specific (Cardiovascular Disease, IRB, NPU, MDS) (DS-CVD-IRB-NPU-MDS) | phs001218.v2.p1 | ||||||||||||||||
55 | GENOA | Genetic Epidemiology Network of Arteriopathy (GENOA) | Hypertension | Prospective Longitudinal Cohort | 1,023 | 2,715 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs001238.v2.p1 | ||||||||||||||||
56 | GENOA | Genetic Epidemiology Network of Arteriopathy (GENOA) | Hypertension | Prospective Longitudinal Cohort | 1,023 | 3,462 | N/A | Disease-Specific (Arteriosclerosis and its Risk Factors, NPU) (DS-ASC-RF-NPU) | phs001238.v2.p1 | ||||||||||||||||
57 | GENOA | NHLBI TOPMed: Genetic Epidemiology Network of Arteriopathy (GENOA) | Hypertension | Family/Twin/Trios | 18 | 1,854 | 1,069 | Disease-Specific (Arteriosclerosis and its Risk Factors, NPU) (DS-ASC-RF-NPU) | phs001345.v2.p1 | ||||||||||||||||
58 | GENSALT | Genetic Epidemiology Network of Salt Sensitivity (GenSalt) | Arterial Pressure, Mean | Interventional | 24 | 101 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000784.v2.p1 | ||||||||||||||||
59 | GENSALT | Genetic Epidemiology Network of Salt Sensitivity (GenSalt) | Arterial Pressure, Mean | Interventional | 24 | 1,675 | N/A | General Research Use (IRB) (GRU-IRB) | phs000784.v2.p1 | ||||||||||||||||
60 | GENSALT | NHLBI TOPMed: Genetic Epidemiology Network of Salt Sensitivity (GenSalt) | Arterial Pressure, Mean | Family/Twin/Trios | 30 | 210 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs001217.v2.p1 | ||||||||||||||||
61 | GENSALT | NHLBI TOPMed: Genetic Epidemiology Network of Salt Sensitivity (GenSalt) | Arterial Pressure, Mean | Family/Twin/Trios | 30 | 3,142 | 888 | Disease-Specific (High blood pressure and related cardiovascular-renal disease, IRB) (DS-HCR-IRB) | phs001217.v2.p1 | ||||||||||||||||
62 | GOLDN | NHLBI TOPMed: GOLDN Epigenetic Determinants of Lipid Response to Dietary Fat and Fenofibrate | Lipids | Prospective Longitudinal Cohort | 19 | 1,069 | N/A | Disease-Specific (Cardiovascular Disease, IRB) (DS-CVD-IRB) | phs001359.v2.p1 | ||||||||||||||||
63 | HCHSSOL | Hispanic Community Health Study /Study of Latinos (HCHS/SOL) | Cardiovascular Disease | Prospective Longitudinal Cohort | 285 | 401 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000810.v1.p1 | ||||||||||||||||
64 | HCHSSOL | Hispanic Community Health Study /Study of Latinos (HCHS/SOL) | Cardiovascular Disease | Prospective Longitudinal Cohort | 285 | 3,681 | N/A | Health/Medical/Biomedical (NPU) (HMB-NPU) | phs000810.v1.p1 | ||||||||||||||||
65 | HCHSSOL | Hispanic Community Health Study /Study of Latinos (HCHS/SOL) | Cardiovascular Disease | Prospective Longitudinal Cohort | 285 | 9,214 | N/A | Health/Medical/Biomedical (HMB) | phs000810.v1.p1 | ||||||||||||||||
66 | HCT_for_SCD | Hematopoietic Cell Transplant for Sickle Cell Disease (HCT for SCD) | Sickle Cell Disease | Prospective Longitudinal Cohort | N/A | 1,518 | N/A | Cure SCi Metadata Catalog | General Research Use (GRU) | phs002385.v1.p1 | |||||||||||||||
67 | HVH | NHLBI TOPMed: Heart and Vascular Health Study (HVH) | Cardiovascular Disease | Case Set | 17 | 697 | 61 | Health/Medical/Biomedical (IRB, MDS) (HMB-IRB-MDS) | phs000993.v3.p2 | ||||||||||||||||
68 | HVH | NHLBI TOPMed: Heart and Vascular Health Study (HVH) | Cardiovascular Disease | Case Set | 17 | 12 | 3 | Disease-Specific (Cardiovascular Disease, IRB, MDS) (DS-CVD-IRB-MDS) | phs000993.v3.p2 | ||||||||||||||||
69 | HVH | Heart and Vascular Health Study (HVH) | Cardiovascular Disease | Case-Control | 41 | 1,179 | N/A | Health/Medical/Biomedical (IRB, MDS) (HMB-IRB-MDS) | phs001013.v3.p2 | ||||||||||||||||
70 | HVH | Heart and Vascular Health Study (HVH) | Cardiovascular Disease | Case-Control | 41 | 25 | N/A | Disease-Specific (Cardiovascular Disease, IRB, MDS) (DS-CVD-IRB-MDS) | phs001013.v3.p2 | ||||||||||||||||
71 | HYPERGEN | NHLBI TOPMed: HyperGEN - Genetics of Left Ventricular (LV) Hypertrophy | Hypertrophy, Left Ventricular | Family/Twin/Trios | 166 | 30,472 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs001293.v2.p1 | ||||||||||||||||
72 | HYPERGEN | NHLBI TOPMed: HyperGEN - Genetics of Left Ventricular (LV) Hypertrophy | Hypertrophy, Left Ventricular | Family/Twin/Trios | 166 | 1,774 | 1,468 | General Research Use (IRB) (GRU-IRB) | phs001293.v2.p1 | ||||||||||||||||
73 | HYPERGEN | NHLBI TOPMed: HyperGEN - Genetics of Left Ventricular (LV) Hypertrophy | Hypertrophy, Left Ventricular | Family/Twin/Trios | 166 | 330 | 284 | Disease-Specific (Cardiovascular Disease, IRB, RD) (DS-CVD-IRB-RD) | phs001293.v2.p1 | ||||||||||||||||
74 | JHS | Jackson Heart Study (JHS) Cohort | Cardiovascular Disease | Prospective Longitudinal Cohort | 4,276 | 1,996 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000286.v6.p2 | ||||||||||||||||
75 | JHS | Jackson Heart Study (JHS) Cohort | Cardiovascular Disease | Prospective Longitudinal Cohort | 4,276 | 883 | N/A | Health/Medical/Biomedical (IRB, NPU) (HMB-IRB-NPU) | phs000286.v6.p2 | ||||||||||||||||
76 | JHS | Jackson Heart Study (JHS) Cohort | Cardiovascular Disease | Prospective Longitudinal Cohort | 4,276 | 201 | N/A | Disease-Specific (Focused Disease Only, IRB, NPU) (DS-FDO-IRB-NPU) | phs000286.v6.p2 | ||||||||||||||||
77 | JHS | Jackson Heart Study (JHS) Cohort | Cardiovascular Disease | Prospective Longitudinal Cohort | 4,276 | 2,289 | N/A | Health/Medical/Biomedical (IRB) (HMB-IRB) | phs000286.v6.p2 | ||||||||||||||||
78 | JHS | Jackson Heart Study (JHS) Cohort | Cardiovascular Disease | Prospective Longitudinal Cohort | 4,276 | 516 | N/A | Disease-Specific (Focused Disease Only, IRB) (DS-FDO-IRB) | phs000286.v6.p2 | ||||||||||||||||
79 | JHS | NHLBI TOPMed: The Jackson Heart Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 26 | 1,992 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000964.v3.p1 | ||||||||||||||||
80 | JHS | NHLBI TOPMed: The Jackson Heart Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 26 | 797 | 686 | Health/Medical/Biomedical (IRB, NPU) (HMB-IRB-NPU) | phs000964.v3.p1 | ||||||||||||||||
81 | JHS | NHLBI TOPMed: The Jackson Heart Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 26 | 180 | 154 | Disease-Specific (Focused Disease Only, IRB, NPU) (DS-FDO-IRB-NPU) | phs000964.v3.p1 | ||||||||||||||||
82 | JHS | NHLBI TOPMed: The Jackson Heart Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 26 | 2,131 | 1,810 | Health/Medical/Biomedical (IRB) (HMB-IRB) | phs000964.v3.p1 | ||||||||||||||||
83 | JHS | NHLBI TOPMed: The Jackson Heart Study | Cardiovascular Disease | Prospective Longitudinal Cohort | 26 | 488 | 424 | Disease-Specific (Focused Disease Only, IRB) (DS-FDO-IRB) | phs000964.v3.p1 | ||||||||||||||||
84 | MAYOVTE | NHLBI TOPMed: Whole Genome Sequencing of Venous Thromboembolism (WGS of VTE) | Venous Thromboembolism | Case Set | 61 | 1,535 | N/A | General Research Use (GRU) | phs001402.v2.p1 | ||||||||||||||||
85 | MESA | Multi-Ethnic Study of Atherosclerosis (MESA) SHARe | Cardiovascular Disease | Prospective Longitudinal Cohort | 22,149 | 1,484 | N/A | Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects | phs000209.v13.p3 | ||||||||||||||||
86 | MESA | Multi-Ethnic Study of Atherosclerosis (MESA) SHARe | Cardiovascular Disease | Prospective Longitudinal Cohort | 22,149 | 7,440 | N/A | Health/Medical/Biomedical (HMB) | phs000209.v13.p3 | ||||||||||||||||
87 | MESA | Multi-Ethnic Study of Atherosclerosis (MESA) SHARe | Cardiovascular Disease | Prospective Longitudinal Cohort | 22,149 | 856 | N/A | Health/Medical/Biomedical (NPU) (HMB-NPU) | phs000209.v13.p3 | ||||||||||||||||
88 | MESA | NHLBI TOPMed: MESA and MESA Family AA-CAC | Cardiovascular Disease | Prospective Longitudinal Cohort | 18 | 4,884 | 4,380 | Health/Medical/Biomedical (HMB) | phs001416.v2.p1 | ||||||||||||||||
89 | MESA | NHLBI TOPMed: MESA and MESA Family AA-CAC | Cardiovascular Disease | Prospective Longitudinal Cohort | 18 | 499 | 450 | Health/Medical/Biomedical (NPU) (HMB-NPU) | phs001416.v2.p1 | ||||||||||||||||
90 | MGHAF | Massachusetts General Hospital (MGH) Atrial Fibrillation Study | Atrial Fibrillation | Case Set | 37 | 933 | N/A | Health/Medical/Biomedical (IRB) (HMB-IRB) | phs001001.v1.p1 | ||||||||||||||||
91 | MGHAF | Massachusetts General Hospital (MGH) Atrial Fibrillation Study | Atrial Fibrillation | Case Set | 37 | 92 | N/A | Disease-Specific (Atrial Fibrillation, IRB, RD) (DS-AF-IRB-RD) | phs001001.v1.p1 | ||||||||||||||||
92 | MGHAF | NHLBI TOPMed - NHGRI CCDG: Massachusetts General Hospital (MGH) Atrial Fibrillation Study | Atrial Fibrillation | Case Set | 17 | 908 | 832 | Health/Medical/Biomedical (IRB) (HMB-IRB) | phs001062.v3.p2 | ||||||||||||||||
93 | MGHAF | NHLBI TOPMed - NHGRI CCDG: Massachusetts General Hospital (MGH) Atrial Fibrillation Study | Atrial Fibrillation | Case Set | 17 | 91 | 84 | Disease-Specific (Atrial Fibrillation, IRB, RD) (DS-AF-IRB-RD) | phs001062.v3.p2 | ||||||||||||||||
94 | MSH | Multicenter Study of Hydroxyurea (MSH) | Sickle Cell Disease | Clinical Trial | N/A | 357 | N/A | Cure SCi Metadata Catalog | General Research Use (GRU) | phs002348.v1.p1 | |||||||||||||||
95 | NSRR-CFS | National Sleep Research Resource (NSRR): Cleveland Family Study (CFS) | Sleep Apnea Syndromes | Prospective Longitudinal Cohort | N/A | 710 | N/A | Disease-Specific (Heart, Lung, Blood, and Sleep Disorders, IRB, NPU) (DS-HLBS-IRB-NPU) | phs002715.v1.p1 | ||||||||||||||||
96 | ORCHID | COVID19-ORCHID | COVID-19 | Clinical Trial | N/A | 479 | N/A | Health/Medical/Biomedical (HMB) | phs002299.v1.p1 | ||||||||||||||||
97 | PARTNERS | NHLBI TOPMed: Partners HealthCare Biobank | Atrial Fibrillation | Case Set | 34 | 128 | 109 | Health/Medical/Biomedical (HMB) | phs001024.v4.p1 | ||||||||||||||||
98 | PCGC | The Pediatric Cardiac Genetics Consortium (PCGC) Study | Heart Defects, Congenital | Prospective Longitudinal Cohort | 437 | 9,431 | N/A | Health/Medical/Biomedical (HMB) | phs001194.v2.p2 | ||||||||||||||||
99 | PCGC | The Pediatric Cardiac Genetics Consortium (PCGC) Study | Heart Defects, Congenital | Prospective Longitudinal Cohort | 437 | 32 | N/A | Disease-Specific (Congenital Heart Disease) (DS-CHD) | phs001194.v2.p2 | ||||||||||||||||
100 | RED_CORAL | PETAL Repository of Electronic Data COVID-19 Observational Study (RED CORAL) | COVID-19 | Control Set | N/A | 1,480 | N/A | Health/Medical/Biomedical (HMB) | phs002363.v1.p1 |